daclizumab
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
| Synonym: | anti-Tac Anti-Tac Humanized Monoclonal Antibody anti-Tac monoclonal antibody Dacliximab |
|---|---|
| US brand name: | Zenapax |
| Abbreviation: | MOAB anti-Tac |
| IND number: | 2091 |